{"id":"nct:NCT00490139","kind":"trial","title":"ALTTO (Adjuvant Lapatinib And/Or Trastuzumab Treatment Optimisation) Study; BIG 2-06/N063D","authors":["Novartis Pharmaceuticals"],"author_count":1,"year":2007,"published":"2007-06-22","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT00490139","source_url":"https://clinicaltrials.gov/study/NCT00490139","archive_url":"https://space-kitty.com/papers/nct:NCT00490139","updated":"2025-03-21","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"This was a four-arm (parallel group) randomized, open-label, multicenter Phase 3 study to investigate the use of a combination of Lapatinib and Trastuzumab, a sequence of Trastuzumab followed by Lapatinib, and Lapatinib alone, compared to Trastuzumab alone in the adjuvant treatment of Human Epidermal Growth Factor Receptor 2 (HER2) positive early breast cancer.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Neoplasms, Breast"],"details":{"acronym":"ALTTO","status":"COMPLETED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":8381,"sponsor":"Novartis Pharmaceuticals","conditions":["Neoplasms, Breast"],"interventions":["DRUG: Lapatinib","BIOLOGICAL: Trastuzumab"],"start_date":"2007-05-16","start_date_type":"ACTUAL","primary_completion_date":"2013-12-06","has_results":true,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"gene-cell-therapy","name":"Gene & Cell Therapy","domain_slug":"medicine"}],"cited_in_dossiers":[]}